BIO Sends Letter to President Trump on U.S.-China Trade & Biotech
December 18, 2018
BIO sent a letter to President Trump following his meeting with President Xi of the People’s Republic of China, welcoming the news the United States and China have begun talks to address important issues including forced technology transfer, intellectual property protection, and agriculture. BIO reminded President Trump of the need to resolve systemic barriers to China’s timely approvals of new agricultural biotechnology products, the approval of all pending products that have languished for years, and intellectual property rights protection of U.S. biomedical products are paramount to continued U.S. innovation, competitiveness, and export growth.
Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…
BIO submitted these comments in response to the United States Patent and Trademark Office’s May 10, 2024, Notice of Proposed Rulemaking regarding Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting.
BIO sent a letter to President Trump following his meeting with President Xi of the People’s Republic of China, welcoming the news the United States and China have begun talks to address important issues including forced technology transfer, intellectual property protection, and agriculture. BIO reminded President Trump of the need to resolve systemic barriers to China’s timely approvals of new agricultural biotechnology products, the approval of all pending products that have languished for years, and intellectual property rights protection of U.S. biomedical products are paramount to continued U.S. innovation, competitiveness, and export growth.